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Synopsis 
This study examines >1000 sentinel node (SN) positive melanoma patients. Time interval 
between primary excision and SN biopsy (SNB) is no prognostic factor for disease free and 
melanoma specific survival. Guidelines advocating SNB <6 weeks should be reconsidered. 
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Abstract 
Background: Worldwide, sentinel node biopsy (SNB) is the recommended staging procedure for 
stage I/II melanoma. Most melanoma guidelines recommend re-excision plus SNB as soon as 
possible after primary excision. To date, there is no evidence to support this timeframe. Aim: To 
determine melanoma specific survival (MSS) for time intervals between excisional biopsy and 
SNB in SNB positive patients. 
Methods: Between 1993-2008, 1 080 patients were diagnosed with a positive SNB in nine 
Melanoma Group centers. We selected 1 015 patients (94%) with known excisional biopsy date. 
Time interval was calculated from primary excision until SNB. Kaplan-Meier estimated MSS 
was calculated for different cutoff values. Multivariable analysis was performed to correct for 
known prognostic factors. 
Results: Median age was 51 years (Inter Quartile Range (IQR) 40-62 years), 535 (53%) were 
men, 603 (59%) primary tumors were located on extremities. Median Breslow thickness was 
3.00mm (IQR 1.90-4.80mm), 442 (44%) were ulcerated. Median follow-up was 36 months (IQR 
20-62 months). Median time interval was 47 days (IQR 32-63 days). Median Breslow thickness 
was equal for both <47 days and ≥47 days interval: 3.00mm (1.90-5.00mm) vs 3.00mm (1.90-
4.43mm) (p=0.402). Sentinel node tumor burden was significantly higher in patients operated 
≥47 days (p=0.005). Univariate survival was not significantly different for median time interval. 
Multivariable analysis confirmed that time interval was no independent prognostic factor for 
MSS.  
Conclusions: Time interval from primary melanoma excision until SNB was no prognostic factor 
for MSS in this SNB positive cohort. This information can be used to counsel patients.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
4 
 
 
Keywords:  Cutaneous Melanoma, Melanoma, Sentinel Lymph Node Biopsy, Melanoma 
Specific Survival, Prognosis, Waiting List. 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
5 
 
 
Manuscript Text 
Introduction 
Parallel to the increasing incidence of primary cutaneous melanomas, sentinel node 
biopsies (SNB) are being performed more often. This is the current standard to detect early 
lymph node micrometastases[1-3].  
As recommended by the American Joint Committee on Cancer (AJCC), as well as the 
American Society of Clinical Oncology (ASCO) and the Society of Surgical Oncology (SSO), by 
performing a SNB, it is possible to provide accurate staging of intermediate thickness (Breslow 
1.0 – 4.0mm) primary cutaneous melanoma[4, 5]. This way, patients can be provided more 
information about their prognosis [4, 6, 7]. Sentinel node (SN) status can help to select patients 
who might benefit from completion lymph node dissection (CLND) and / or adjuvant systemic 
therapies in trial setting, for instance the EORTC 18991 study on pegylated interferon alfa and 
the EORTC 18071 study on ipilimumab[8, 9]. Currently  no uniform recommendation exists on 
the maximum allowed time interval between primary melanoma excision and wide local excision 
(WLE) combined with SNB. Most national melanoma guidelines advise to perform WLE and 
SNB as soon as possible within an acceptable time frame. The Dutch national melanoma 
guideline advocates a strict maximum time interval of six weeks[10]. This suggests a detrimental 
effect on survival if not adhered to. To date, only two studies have reported on this topic. Parrett 
et al. found no adverse effects on survival for a time interval of <40 days vs. > 40 days, while 
Tejera-Vaquerizo et al. reported a detrimental effect of a time interval of <40 days at the expense 
of SN negative patients[11, 12]. These contradicting findings are not sufficient to answer the 
question which effects, if any, time interval may have on survival.  
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One of the negative aspects of advising a short time frame for SNB is the incentive for 
general practitioners (GP’s) and dermatologists to perform high urgency referrals. The potentially 
increased patient anxiety due to longer wait times (depending on the country’s healthcare system) 
may also play a considerable role in this. Altogether this poses the need to objectively describe 
the possible influences of the time interval between primary diagnosis and WLE plus SNB on 
survival. We hypothesize that this time interval may be associated with a difference in survival. 
Aim of the study is to investigate if time interval between primary diagnosis and WLE plus SNB 
is associated with survival differences in a SN positive melanoma population.   
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Methods 
Patients 
For purposes of this current study, a retrospective cohort of SN positive patients, 
previously collected and described, was used[13]. In brief, this cohort contained 1 080 SN 
positive patients from nine European Organization for Research and Treatment of Cancer 
(EORTC) Melanoma Group centers, undergoing SNB between 1993 and 2008. The study was 
performed in accordance with local ethics committee guidelines. In total, 1 015 patients (94%) 
were selected with known date of primary melanoma excision. Collected data included: gender, 
age, date of primary excision, date of SNB, primary tumor characteristics i.e. location, Breslow 
thickness, ulceration, CLND data i.e. performed yes/no, positive non-SNs yes/no, and follow-up 
(FU). 
 
Melanoma Diagnosis 
Diagnosis of the primary melanoma was based on histopathologic examination of  an 
excisional biopsy in all cases. Excisional biopsy was performed with total thickness excision and 
a narrow margin, as described in the American Association of Dermatology Guidelines and the 
National Cancer Comprehensive Network Clinical Practice Guidelines[14, 15].  Date of 
diagnosis was defined as the date of excisional biopsy. All patients treated at the participating 
centers were worked up for SNB in line with the recommendations stated by the European 
Society of Medical Oncology [16].   
 
Surgical Procedure and Pathology:  
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SNB was performed if Breslow thickness was > 1.0 mm or if risk factors were present 
such as ulceration or high Clark level (IV or V), regression, or high mitotic rate (>1 count/field). 
Generally, WLE (with a margin of 1-2 cm depending on the Breslow thickness) and SNB were 
performed in the same setting. In all centers the triple technique was used for SNB; consisting of 
pre-operative lymphoscintigraphy within 24 hours prior to the procedure; perioperative injection 
of patent blue near the primary tumor site and use of an intraoperative handheld gamma detection 
probe to locate the SN(s) [17, 18]. A lymph node was defined as SN, if it was blue and / or hot 
(in situ: intraoperative gamma detector count of at least 3x background count, ex situ: 
intraoperative gamma detector count of at least 10x background count)[13]. Pathology review 
and reports were conducted according to the EORTC Melanoma Group Pathology Protocol, 
including scoring of SN tumor burden according to the Rotterdam criteria  [19-21]. 
 
Outcome measures:  
Time interval until SNB was the variable of interest (dependent variable) in this study. 
The primary endpoint was melanoma specific survival (MSS). Secondary endpoints were disease 
free survival (DFS); overall survival (OS); and SN tumor burden.  
 
Statistics 
Time until SNB was calculated from date of diagnosis until SNB date. FU was calculated 
from SNB date to last FU date or death.  DFS was calculated from SNB date until date of first 
recurrence (any site). OS was calculated from SNB date until death (any cause) or last FU. MSS 
was calculated from SNB date until death by melanoma or last FU, deaths by other causes were 
censored (considered as withdrawal from population). 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
9 
 
 
Patients were divided into two categories based on time interval: early SNB (< median) 
vs, late SNB (≥ median). Additionally, the first (Q1) and third quartile (Q3) of time interval were 
tested as binominal categories, and first (Q1) and last quartile (Q4) were tested against each other 
to detect differences between both outer quartiles. Breslow thickness, ulceration, SN tumor 
burden, gender and location of the primary tumor were analyzed per time interval category in 
order to investigate the possibility of differences in distribution indicating a selection bias in 
favor of early or late SNB. Kaplan-Meier estimated MSS was calculated per time interval 
category. Cox proportional hazard multivariable analysis was performed adjusting for age, 
gender, Breslow thickness, histology type, ulceration, Clark level, SN tumor burden, CLND 
category (performed/not performed), additional positive non-SNs  and time interval as continuous 
variable. The maximum allowed degrees of freedom in the model were based on the number of 
events, not exceeding one tenth of the number of events.  
A p-value of <0.05 was considered statistically significant. All statistical analyses were 
performed using SPSS Version 21.0 (IBM Corp. Released 2012. IBM SPSS Statistics for 
Windows, Version 21.0. Armonk, NY: IBM Corp.).   
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Results 
In total 1 015 patients (93.9%) were selected of whom diagnosis date was known and time 
interval was less than 154 days (22 weeks). Median age at diagnosis was 51 years (IQR 40-62 
years). Median FU was 36 months (IQR 20 -62 months), median DFS was 27 months (11 – 57 
months). Table 1 summarizes the baseline characteristics of the study population per time 
interval category.  
Regression and mitotic rate were only recorded in a minority of patients, hence these 
variables were not included for further analysis. Median Breslow thickness was 3.00 mm (IQR 
1.90 – 4.80mm). Median time interval per center is shown in table 2. The proportion of patients 
undergoing SNB early (<47 days) differed significantly per center, due to more early surgical 
procedures in Center 2 and Center 9 (operated within 47 days: 95.3% and 60.9% vs. 23.9% - 
56.6%  in the remaining centers) (table 1, table 2). edian FU did not differ between patients 
operated at <47 days (37 months, IQR 19 – 62 months) vs. patients operated at ≥47 days (35 
months, IQR 21 – 62 months) (p=0.632).  
5-year Estimated Kaplan-Meier MSS showed no significant difference in survival for 
early SNB (<47 days) vs. late SNB (≥ 47 days) (Figure 1). For time interval categories Q1 and 
Q3 respectively, also no significant difference in MSS or DFS was seen (data not shown). 
Survival was not different between both outer quartiles; 5-yr MSS for Q1 (<32 days) was 70%  
vs. 72% for Q4 (>63 days), p=0.574 (Figure 2). 
Univariable logistic Cox regression analyses showed a significant difference in 5-year 
estimated MSS for the following variables: older age (as continuous variable), gender, 
histological subtype, Clark level, ulceration, Breslow thickness, SN tumor burden, and positive 
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non-SNs at CLND (table 3). Non-significant on univariable analyses were: primary tumor 
location, center, CLND category and time interval (as continuous variable).  
A Cox proportional hazard multivariable analysis was performed with inclusion of the 
significant factors on univariable analyses as mentioned above, CLND category and  time 
interval to adjust for any possible occult selection bias on univariable analysis. Only male gender, 
presence of ulceration, higher Breslow thickness, SN tumor burden >0.1mm and positive non-
SNs at CLND remained as independent prognostic factors for 5 year MSS (table 3). Time 
interval from primary excision to SNB was no independent prognostic factor for 5 year MSS 
after adjustment for potential confounding factors on multivariable analysis. DFS and OS were 
calculated for the entire cohort and each co-variable per time interval category (results not 
shown). Results were similar to the MSS data, namely that time interval was not a prognostic 
factor. For DFS, the following additional prognostic indicators were found: increasing age (HR 
1.01, 95% CI 1.00 – 1.01, p=0.050), center 2 (HR 0.59, 95% CI 0.35 – 0.98, p=0.040), center 4 
(HR 0.51, 95% CI 0.31 – 0.83, p=0.006), center 5 (HR 0.47, 95% CI 0.29– 0.77, p=0.002), 8 (HR 
0.33, 95% CI 0.17 – 0.62, p=0.001) and 9 (HR 0.24, 95% CI 0.12 – 0.48, p=0.001), and Clark 
level IV (HR 2.07, 95% CI 1.01 – 4.24, p=0.048) and V (HR 2.21, 95% CI 1.03 – 4.76, p=0.042).  
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Discussion 
The MSLT 1 final report showed no difference in 10-year MSS for WLE and SNB 
followed by immediate CLND versus WLE alone and nodal observation followed by delayed 
therapeutic lymph node dissection if necessary [22]. Sub analyses in node positive patients with 
intermediate-thickness melanoma (1.2-3.5mm) showed a significantly improved 10-year distant 
DFS and MSS in favor of SNB. Considering this, any potential impact of the time interval until 
SNB on survival might more likely become detectable in patients with nodal disease, i.e. a 
positive SN. This formed the rationale to perform the current study with SN positive patients.    
In this study, 5-year estimated MSS is not significantly different for short versus longer 
time intervals (Figure 1, figure 2). SN tumor burden according to the Rotterdam criteria [13, 20] 
is significantly more often high in those patients undergoing SNB after a time interval of 47 days 
or more. Thus it may seem that late performance of SNB might have an adverse effect on tumor 
burden. Oppositely of the increase of SN tumor burden with a longer time interval, the risk of 
additional positive non-SNs at CLND was higher in patients with early SNB (≤47 days). In 
multivariable logistic regression (data not shown), time interval was not correlated to CLND 
outcome, but Center was. This has been addressed by van der Ploeg et al[23]. Since time 
intervals are different between centers (table 2), there is a strong correlation between center and 
time interval. This could explain why it would seem that time interval has influence on the 
proportion of patients with positive non-SNs at CLND while in truth proportion of positive non-
SNs is associated with the center of treatment.  
After correcting for tumor burden, CLND outcome, and other known prognostic factors in 
a multivariable model time interval cannot be identified as a detrimental prognostic factor for 
MSS. This is in line with the study of Parrett et al. which concerned 491 SN positive and negative 
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patients from a single institution[12]. With a  median time interval of 40 days,  no differences in 
DFS, OS and MSS were found, nor any significant difference in SN positivity rates.  
Importantly, the current study consists of SN positive patients only. Since SN positive 
patients have a worse prognosis, the outcome of this study strengthens the findings of Parrett et 
al. SN negative patients have not been investigated in the current study, but effect of time interval 
on survival is not expected in these  low-risk patients. Interestingly, Tejera-Vaquerizo et al. did 
find a detrimental effect of a short time interval on survival for SN negative patients[11]. They 
hypothesized that a shorter time interval and worse prognosis were associated due to surgeons 
prioritizing patients for surgery when primary tumor features were worrisome. Validation of 
these data is needed, as the described findings are counterintuitive.   
The phenomenon that high SN tumor burden was more frequently observed in those 
patients undergoing SNB at a later time interval might cause one to consider a correlation 
between SN tumor burden and time interval.   
When stratifying for SN tumor burden in Kaplan-Meier estimated survival analyses, no 
significant differences in MSS are seen for time interval (data not shown). After stratification for 
time interval <47 days vs. >47 days, SN tumor burden did distinguish clearly between good, 
intermediate and poor prognosis (Figure S1).  The fact that there was no unadjusted survival 
difference between the group with a time interval of <47 days versus the group with a time 
interval of ≥ 47 days while the proportion of patients with a high SN tumor burden was slightly 
larger in the latter may be explained by the fact that survival is influenced by many variables and 
that the net effect canceled out the slightly more frequent high SN tumor burden in the latter 
group. The fact that survival for high SN tumor burden found with early SNB versus high SN 
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tumor burden found with late SNB is not different confirms that SN tumor burden is a prognostic 
factor regardless of  SNB timing.  
It is remarkable that there are differences in DFS across centers and not in MSS. Due to 
the retrospective nature of this study, the exact timing of follow-up visits is not known for all 
centers. It could be that more frequent follow-up visits in these centers led to a lead-time bias 
effect. Another possibility could be that these centers treated more patients with low risk 
primaries. This was not the case, since centers with a low median Breslow thickness had more 
ulcerated tumors and vice versa. As detailed follow-up information including date and site of first 
recurrence was not known for all patients, the lower HR for DFS  in five  out of nine participating 
centers may also be explained by a selection bias due to missing data.  
There is sparse literature with regard to the maximum allowable time interval for SNB. 
Two large prospective trials have included a maximum time interval as inclusion criterion. These 
are the MSLT I trial, with a maximum allowed time interval to SNB of 12 weeks [24], and the 
SUNBELT trial, where the maximum allowed time interval was 90 days (=13 weeks) [25]. This 
maximum time interval is at least two times as high as the median time interval found in the 
current cohort. These time intervals seem to be reasonable in the light of providing treatment 
within a timely manner, and at the same time allowing an adequately broad window for 
scheduling SNB. As for WLE, which is often combined with SNB: McKenna et al. reported long 
term survival data of a large retrospective cohort showing no differences in recurrence free 
survival and OS regardless of the time interval until WLE [26]. While time interval until SNB is 
not prognostic for survival in the current study, it can be used as a quality measure for hospitals 
performing SNB. This could form an addition to registration of SN positivity rate per hospital, 
another recently proposed quality measure[27]. 
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There are limitations in the current study. It is a retrospectively collected cohort from nine 
tertiary referral melanoma institutes across Europe. Inevitably, this can cause a selection bias, due 
to differences in local patient population, patient selection and protocols per center. As all centers 
are EORTC Melanoma Group centers, there is much expertise in work up and treatment of 
melanoma patients. Uniform work up of patients eligible for SNB, surgery and histopathological 
analysis of the SN was already applied in all these centers prior to implementation into European 
consensus guidelines. Local differences will have mainly consisted of referral policies, wait lists 
and case-mix rather than technical approaches to melanoma patients.  
In the current cohort adjuvant interferon therapy was not used as a covariate, as only a 
minority of patients received interferon in adjuvant trial setting (n=36), and for one third of all 
patients no information was available on trial participation. Primary melanomas in the head and 
neck region seem to be underrepresented, and median Breslow thickness varies considerably per 
center. Also the number of thick melanomas is high (Table 1). One possible explanation for this 
may be the fact that all participating centers are EORTC Melanoma Group referral centers, with a 
corresponding high risk case-mix. Considering this, the current cohort may not be entirely 
representative for the general population that would normally be offered a SNB. To overcome 
this, multivariable analyses have been performed to correct for known prognostic and potential 
confounding factors. The FU is limited, and an update of follow up data would definitely 
improve the value of the current study. During the median FU of  36 months (3 years) DFS and 
MSS were not affected by time interval, which is considerable. As this cohort consists of SN 
positive patients only, it is by definition not representative for the entire population undergoing 
SNB. It does reflect a wide variety of SN positive patients, including patients with thin 
melanomas and patients with thick melanomas.  
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Since no differences in survival are found for different time intervals in this high risk SN 
group, survival differences for the more beneficial SN negative patient population are unlikely. 
One has to take into account that although no effects on survival were seen for SN positive 
patients, SN-positivity rate might be adversely influenced by a longer time interval. No 
conclusions can be drawn on this aspect with the current SN positive cohort alone.   
Finally, although a fixed maximum time interval based on survival does not seem to be 
necessary, minimizing the amount of wait time to surgery is still important to ease patient 
anxiety, as it affects the daily life of most patients. A survey by Eskander et al. in patients 
undergoing elective malignant thyroid surgery showed that anxiety levels significantly decreased 
after surgery, suggesting that stress and anxiety levels can be minimalized by performing surgery 
timely [28]. Another study by Oudhoff et al. concerning surgery for benign disorders, reported an 
increase in negative emotional reactions to waiting, significantly associated with wait time, which 
decreased significantly after surgery[29].  
Taking all of the above into consideration, the need to perform early SNB as advised by 
specific melanoma guidelines should be reconsidered. As there is no solid base to adhere to a 
maximum time interval between WLE and SNB as stated in the above, maintaining a time 
interval falsely suggests that there still is a clinicopathological ground for performing SNB as 
soon as possible. This may facilitate unnecessary patient anxiety for patients on waiting lists. We 
therefore suggest that international melanoma guidelines should revise the need of a timeframe 
for SNB after primary melanoma excision in order to reduce patient anxiety and pressure on 
surgeon’s schedule. 
 
Conclusions 
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Time interval between primary melanoma excision and wide local excision (WLE) 
combined with Sentinel Node Biopsy (SNB) did not influence 5-year estimated DFS and MSS in 
a population of SN positive patients. Patients who got their SNB later had a slightly larger 
disease deposit and although this may have implications for prognosis this study did not detect 
any difference. These findings indicate that it is safe and equally informative to perform SNB 
after a prolonged interval of >9 weeks(4th quartile). This information can be used to counsel 
patients.  
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Figure Captions 
Figure 1. 5 Year Estimated Melanoma Specific Survival (MSS) for Median Sentinel Node 
Biopsy (SNB) Time Interval. 
5-year estimated melanoma specific survival (MSS) in months for time interval <47 days (blue 
line) and ≥47 days (red line).  
 
Figure 2. 5 Year Estimated Melanoma Specific Survival (MSS) for Sentinel Node Biopsy 
(SNB) Time Interval Outer Quartiles. 
5-year estimated melanoma specific survival (MSS) in months for first quartile Q1, <32 days 
(blue line) and fourth quartile Q4, >63 days (red line).  
 
Supplementary: 
Figure S1 5 Year Estimated Melanoma Specific Survival (MSS) for Sentinel Node (SN) 
Tumor Burden Stratified for Time Interval. 
5-year estimated melanoma specific survival (MSS) in months stratified for a time interval until 
SN biopsy of <47 days (A) and a time interval of ≥ 47 days (B) for sentinel node (SN) tumor 
burden categories <0.1 mm (yellow line), 0.1-1.0mm (blue line), and >1.0mm (red line)  
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Tables 
Table 1. Baseline Characteristics of Sentinel Node Positive Patients (N = 1 015) 
Characteristic < 47 days ≥ 47 days All p 
N (%) 507 (50) 508 (50) 1 015 (100)  
Center      
1     53 (10.5)   62 (12.2) 115 (11.3)  
2     82 (16.2)     4 (0.8)   86 (8.5)  
3   101 (19.9) 120 (23.6) 221 (21.8)  
4   102 (20.1) 102 (20.1) 204 (20.1)  
5     22 (4.3)   70 (13.8)   92 (9.1)  
6     25 (4.9)   41 (8.1)   66 (6.5)  
7     60 (11.8)   46 (9.1) 106 (10.4)  
8     20 (3.9)   36 (7.1)   56 (5.5)  
9     42 (8.3)   27 (5.3)   69 (6.8) 0.005* 
Gender     
    Female 228 (45.0) 252 (49.6) 480 (47.3)  
    Male 279 (55.0) 256 (50.4) 535 (52.7) 0.139 
Age, years     
    ≤ 51 255 (50.3) 264 (52.0) 520 (51.1)  
    > 51 252 (49.7) 244 (48.0) 496 (48.9) 0.594 
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Table 1. Baseline Characteristics of Sentinel Node Positive Patients (N = 1 015), continued 
Location     
    Extremity 314 (61.9) 289 (56.9) 603 (59.4)  
    Trunk 177 (34.9) 204 (40.2) 381(37.5)  
    Head/neck   16 (3.2)   15 (3.0)   31 (3.1) 0.122 
Histology     
    SSM 179 (35.3) 197 (38.8) 376 (37.0)  
    NM 172 (33.9) 157 (30.9) 329 (32.4)  
    Other   25 (4.9)   15 (3.0)   40 (4.0)  
    Unknown 131 (25.8) 139 (27.4) 270 (26.6) 0.538 
Breslow Thickness, mm    
    T1 (</= 1.00)   29 (5.7)   20 (3.9)   49 (4.8)  
    T2 (1.01-2.00) 118 (23.3) 139 (27.4) 257 (25.3)  
    T3 (2.01-4.00) 201 (39.6) 210 (41.3) 411 (40.5)  
    T4 (>4.00) 159 (31.4) 137  (27.0) 296 (29.2)  
    Missing -     2 (0.4)     2 (0.2) 0.236 
Clark level     
    II   12 (2.4)   20 (3.9)   32 (3.2)  
    III 120 (23.7) 133 (26.2) 253 (24.9)  
    IV 309 (60.9) 276 (54.3) 585 (57.6)  
    V   48 (9.5)   52 (10.2) 100 (9.9)  
    Unknown   18 (3.6)   27 (5.3)   45 (4.4) 0.567 
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Table 1. Baseline Characteristics of Sentinel Node Positive Patients (N = 1 015), continued 
Ulceration     
    Absent 249 (49.1) 262 (51.6) 511 (50.3)  
    Present 229 (45.2) 213 (41.9) 442 (43.5)  
    Unknown   29 (5.7)   33 (6.5)   62 (6.1) 0.550 
SN tumor burden     
<0.1mm   60 (11.8)   52 (10.2) 112 (11.0)  
0.1 – 1.0mm 238 (46.9) 199 (39.2) 437 (43.1)  
>1.0mm 209 (41.2) 257 (50.6) 466 (45.9) 0.005* 
CLND performed     
    No   24 (4.7)   22 (4.3)   46 (4.5)  
    Yes 468 (92.3) 482 (94.9) 950 (93.6)  
    Unknown   15 (3.0)     4 (0.8)   19 (1.9) 0.276 
Positive non SNs     
    No 380 (75.0) 415 (81.7) 795 (78.3)  
    Yes 110 (21.7)   87 (17.1) 197 (19.4)  
    Unknown     17 (3.4)     6 (1.2)     23 (2.3) 0.009* 
Time interval, 
median (IQR) 
32 (26 – 40) 63 (54 – 75) 47 (32 – 63) 0.331 
N, number of patients; IQR, inter quartile range; SSM, superficial spreading melanoma; NM, 
nodular melanoma; LMM, lentigo maligna melanoma; ALM, acrolentiginous melanoma; 
CLND, completion lymph node dissection; SN, sentinel node. * significance reached at p<0.05. 
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Table 2. Time Interval Between Melanoma Diagnosis and Sentinel Node Biopsy per Center 
Center  Time interval in days: median, (inter quartile range) 
1 48 (36 – 61) 
2 9 (0 - 30) 
3 49 (36 – 63) 
4 47 (33 – 61) 
5 63 (48 – 73) 
6 53 (37 – 69) 
7 41 (29 – 62) 
8 50 (41 – 64) 
9 37 (21 – 59) 
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Table 3. Univariable and Multivariable Analysis on 5 Year Melanoma Specific 
Survival (MSS) (N = 1 015) 
 Univariable Multivariable 
Covariate HR 95% CI P HR 95% CI P 
Age, continuous 1.01 1.00 – 1.02 0.043* 1.01 0.99 – 1.01  0.322 
Gender       
    Female 1   1   
    Male 1.31 1.00 - 1.72 0.046* 1.37 1.04 – 1.81 0.024* 
Histology             
    SSM 1      1     
    NM 1.40 1.01 - 1.93 0.042* 0.96 0.68 – 1.35  0.959 
    Other 2.04 1.10 - 3.76 0.023*  1.75  0.92 – 3.34 0.088 
    Unknown 1.39 0.98 - 1.99 0.065  1.32  0.89 – 1.95 0.170 
Clark level       
    II 1   1   
    III 1.34 0.48 - 3.75 0.576 1.61 0.57 - 4.57 0.372 
    IV 1.98 0.73 - 5.36 0.178 2.09 0.77 - 5.73 0.150 
    V 3.84 1.37 - 10.8 0.011* 2.42 0.84 - 6.96 0.101 
    Unknown 2.70 0.86 - 8.47 0.090 2.21 0.67 - 7.28 0.194 
Ulceration             
    Absent 1     1     
    Present 2.19 1.65 - 2.91 <0.0001* 1.67 1.24 - 2.26 0.001* 
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Table 3. Univariable and Multivariable Analysis on 5 Year Melanoma Specific 
Survival (MSS) (N = 1 015), Continued 
    Unknown 1.73 0.98 - 3.05 0.059 1.44 0.77 – 2.70 0.254 
Breslow, 
continuous 
1.07 1.06 – 1.09 <0.0001* 1.05 1.02 – 1.07 0.0002* 
Tumor burden             
    < 0.1 mm 1     1     
    0.1 – 1.0 mm 3.20 1.48 - 6.93 0.003* 2.85 1.31 - 6.21 0.008* 
    > 1.0 mm 5.96 2.79 - 12.7 <0.0001* 4.14 1.91 – 9.00 0.0003* 
CLND done       
No 1   1   
Yes 1.12 0.53 – 2.37 0.775 0.63 0.29 – 1.37 0.244 
Unknown 1.99 0.58 – 6.81 0.271 0.61 0.06 – 6.29 0.674 
Positive non-
SNs 
      
    No 1   1   
    Yes 2.47 1.86 – 3.28 <0.0001* 2.27 1.68 – 3.05 <0.0001* 
    Unknown 2.37 0.97 – 5.79 0.058 2.51 0.34 – 18.4 0.366 
Time interval, 
continuous 1.00 0.99 – 1.01 0.721 1.00 0.99 – 1.01 0.567 
Abbreviations: MSS, melanoma specific survival; N, number of patients; HR, Hazard 
Ratio; 95% CI, 95% Confidence Interval; *, significant at p<0.05; SSM, superficial 
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Table 3. Univariable and Multivariable Analysis on 5 Year Melanoma Specific 
Survival (MSS) (N = 1 015), Continued 
spreading melanoma; NM, nodular melanoma; n.s., not significant; CLND, completion 
lymph node dissection; SN, sentinel node. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
View publication stats
